Jay L. Koyner, MD, is a Professor of Medicine in the Section of Nephrology at the University of Chicago where he also serves as the Medical Director of the Inpatient Dialysis Unit, Director of ICU Nephrology and the Associate Program Director of the Nephrology-Critical Care Fellowship. His clinical and research focus centers on critical care nephrology including the earlier detection of acute kidney injury (AKI) using machine-learning risk scores and novel biomarkers of tubular injury as well as improving the care delivery of patients with AKI especially those receiving continuous renal replacement therapy.
For nearly two decades Dr. Koyner has been a national and international leader in AKI research. He has contributed to the development and FDA validation of several new biomarkers as well as the standardization of the furosemide stress test, all of which can be used for more accurate prediction for the development of severe AKI. Having worked to bring these tools from research studies to clinical use his work has improved the care of patients at risk for AKI as well as those with established early AKI.
In addition to his research efforts, Dr. Koyner is an accomplished educator having created and directed the Nephrology fellowship’s Intensive Care Unit rotations. On the national level he has directed the American Society of Nephrology’s Critical Care Nephrology pre-course and edited of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology. More recently he has served as the primary editor of the Handbook of Critical Care Nephrology.
Dr. Koyner is actively involved in training the next generation of critical care nephrologists as well as residents, medical students and undergraduates. He has published over 100 peer reviewed articles, book chapters and consensus care documents and has served on the editorial boards of several prominent nephrology and critical care journals.
As the medical director of the inpatient acute dialysis unit, he continues to innovate and provide cutting edge care to hospitalized patients at the University of Chicago. This includes establishing a Molecular Adsorbent Recirculating System (MARS) program to improve the care of patients with combined liver-kidney injury as well as establishing protocols to assist in administrating Chimeric Antigen Receptor T-Cell (CAR-T) therapy to patients with end-stage kidney disease and dialysis requiring AKI.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
The Impact of the Selective Cytopheretic Device on Neutrophil-to-Lymphocyte Ratios and Hematological Parameters in AKI: A Pooled Analysis.
The Impact of the Selective Cytopheretic Device on Neutrophil-to-Lymphocyte Ratios and Hematological Parameters in AKI: A Pooled Analysis. Nephron. 2025 May 30; 1-19.
PMID: 40451159
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS).
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
PMID: 40448185
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe AKI.
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe AKI. Clin J Am Soc Nephrol. 2025 Apr 15; 20(6):766-778.
PMID: 40232856
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research.
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Apr; 51(4):836-839.
PMID: 40163136
A common longitudinal intensive care unit data format (CLIF) for critical illness research.
A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Mar; 51(3):556-569.
PMID: 40080116
Acute Kidney Injury and Critical Care Nephrology.
Acute Kidney Injury and Critical Care Nephrology. Adv Kidney Dis Health. 2025 Jan; 32(1):12-23.
PMID: 40175025
Can we use artificial intelligence to better treat acute kidney injury?
Can we use artificial intelligence to better treat acute kidney injury? Intensive Care Med. 2025 Jan; 51(1):160-162.
PMID: 39661141
The authors reply.
The authors reply. Crit Care Med. 2024 Dec 01; 52(12):e632.
PMID: 39637273
10 tips on how to use dynamic risk assessment and alerts for AKI.
10 tips on how to use dynamic risk assessment and alerts for AKI. Clin Kidney J. 2024 Nov; 17(11):sfae325.
PMID: 39588357
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial. EClinicalMedicine. 2024 Oct; 76:102830.
PMID: 39318788
Mid-Career Award
American Society of Nephrology
2019